{"id":11420,"date":"2011-05-20T00:00:00","date_gmt":"2011-05-19T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/es\/blog\/2011\/05\/20\/investigadores-del-idibell-identifican-un-nuevo-gen-asociado-al-riesgo-de-sufrir-cancer-de-mama\/"},"modified":"2020-05-26T12:04:45","modified_gmt":"2020-05-26T10:04:45","slug":"investigadores-del-idibell-identifican-un-nuevo-gen-asociado-al-riesgo-de-sufrir-cancer-de-mama","status":"publish","type":"post","link":"https:\/\/idibell.cat\/es\/2011\/05\/investigadores-del-idibell-identifican-un-nuevo-gen-asociado-al-riesgo-de-sufrir-cancer-de-mama\/","title":{"rendered":"Investigadores del IDIBELL identifican un nuevo gen asociado al riesgo de sufrir c\u00e1ncer de mama"},"content":{"rendered":"
Un estudio internacional liderado por investigadores del Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL) ha identificado un nuevo gen implicado en la susceptibilidad de sufrir c\u00e1ncer de mama.<\/strong> Un estudio internacional liderado por investigadores del Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL) ha identificado un nuevo gen implicado en la susceptibilidad de sufrir c\u00e1ncer de mama. Referencia del art\u00edculo Evidence for a link between TNFRSF11A and risk of Breast Cancer.<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[184,292,281,223],"tags":[],"class_list":["post-11420","post","type-post","status-publish","format-standard","hentry","category-area-cancer","category-cancer-de-mama-cancer-2","category-programa-de-mecanismos-moleculares-y-terapia-experimental-en-oncologia-oncobell","category-transformacion-y-metastasis"],"publishpress_future_action":{"enabled":false,"date":"2025-04-10 18:21:16","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=11420"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11420\/revisions"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=11420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=11420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=11420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Un estudio internacional liderado por investigadores del Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL) ha identificado un nuevo gen implicado en la susceptibilidad de sufrir c\u00e1ncer de mama. El trabajo coordinado por Miquel \u00c0ngel Pujana, jefe del grupo de investigaci\u00f3n en C\u00e1ncer de Mama, y por Eva Gonz\u00e1lez-Su\u00e1rez jefe de grupo de investigaci\u00f3n de Transformaci\u00f3n y met\u00e1stasis, se ha publicado en la revista Breast Cancer Research and Treatment.
Desde hace a\u00f1os se conocen dos genes, el BRCA1 y el BRCA2 que, cuando est\u00e1n mutados, aumentan mucho el riesgo de sufrir un c\u00e1ncer de mama. Por otro lado, estudios recientes han identificado modificadores de la penetrancia de mutaciones de BRCA1\/2<\/em> que tambi\u00e9n influyen en el riesgo de sufrir
c\u00e1ncer en
la poblaci\u00f3n general. En este contexto, el estudio ha analizado variantes gen\u00e9ticas del gen TNFRSF11A, que codifica para la prote\u00edna RANK y tiene un papel fundamental en el proceso de desarrollo y diferenciaci\u00f3n de las c\u00e9lulas del epitelio de la mama y en el de iniciaci\u00f3n de tumores de mama. Los investigadores han visto que las portadoras del alelo menor de la variante gen\u00e9tica rs7226991 tienen un riesgo reducido de sufrir c\u00e1ncer de mama. Es necesario destacar que esta asociaci\u00f3n se ha encontrado tanto en pacientes espor\u00e1dicas, de la poblaci\u00f3n general, como en casos familiares de portadoras de mutaciones en el gen BRCA2.
EL objetivo del grupo de investigaci\u00f3n es incluir esta nueva informaci\u00f3n gen\u00e9tica ente los algoritmos de decisi\u00f3n que se utilizan en las unidades de consejo gen\u00e9tico por mejorar el seguimiento de las pacientes con una alta predisposici\u00f3n de sufrir el c\u00e1ncer. En el estudio han participado el Instituto Catal\u00e1n de Oncolog\u00eda (ICO), el Centro Nacional de Investigaci\u00f3n Oncol\u00f3gica (CNIO), el Instituto de Oncolog\u00eda del Hospital Vall d\u2019Hebron (VHIO), el Hospital de la Santa Creu i Sant Pau, el Hospital Universitario Miguel Servet de Zaragoza, el Hospital Cl\u00ednico San Carlos de Madrid y otros centros de Israel e Italia.
Referencia del art\u00edculo <\/strong>
<\/strong> Bonifaci N., Palafox M., Pellegrini P. et. al. Evidence for a link between TNFRSF11A and risk of Breast Cancer. <\/strong>Breast Cancer Research and Treatment. 2011 May 4. doi: 10.1007\/s10549-011-1546-7<\/p>\n","protected":false},"excerpt":{"rendered":"